Killing time for cancer cells

Nature Reviews Cancer

Volumn 5, Issue 7, 2005, Pages 573-580

  Klein, Shoshana ^a   McCormick, Frank ^b   Levitzki, Alexander ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIMITOTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; CANCER GROWTH FACTOR; CELL CYCLE INHIBITOR; CELL DNA; CISPLATIN; CYCLIN B; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYCLIN DEPENDENT KINASE INHIBITOR; DASATINIB; ERLOTINIB; FLAVOPIRIDOL; GEFITINIB; GEMCITABINE; GROWTH FACTOR RECEPTOR; GUANOSINE TRIPHOSPHATASE; GX 15 070; IMATINIB; MITOGEN ACTIVATED PROTEIN KINASE; OBLIMERSEN; ON 012380; PROTEIN INHIBITOR; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; RAF PROTEIN; RAS PROTEIN; SORAFENIB; SUNITINIB; TAXANE DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN RECEPTOR;

APOPTOSIS; CANCER CELL; CANCER CONTROL; CANCER INHIBITION; CANCER RECURRENCE; CANCER SURVIVAL; CELL CLONE; CELL DEATH; CELL DIVISION; CELL KILLING; CELL PROLIFERATION; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; DNA DAMAGE; DRUG EFFICACY; DRUG SELECTIVITY; DRUG SENSITIVITY; DRUG TARGETING; DRUG WITHDRAWAL; GENE MUTATION; HUMAN; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; STEM CELL; TREATMENT FAILURE; TUMOR REGRESSION; TUMOR SUPPRESSOR GENE;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL PROLIFERATION; HUMANS; NEOPLASMS; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION;

EID: 21744449674     PISSN: 1474175X     EISSN: None     Source Type: Journal    
DOI: 10.1038/nrc1651     Document Type: Review

References (67)

1. Benhar, M., Engelberg, D. & Levitzki, A. ROS, stress-activated kinases and stress signalling in cancer. EMBO Rep. 3, 420-425 (2002).
2. Yaish, P. et al. Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science 242, 933-935 (1988).
3. Leviteki, A. & Gazit, A. Tyrosine kinase inhibition: an approach to drug development. Science 267 1782-1788 (1995).
4. Levitzki, A, Signal-transduction therapy. A novel approach to disease management Eur. J. Biochem. 226, 1-13 (1994).
5. Soengas, M. S. & Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138-3151 (2003).
6. Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF/ MEK/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis. Cancer Res, 64, 7099-7109 (2004).
7. Karasarides, M. et al. B-RAF is a therapeutic target in melanoma. Oncogene 23, 6292-6298 (2004).
8. ARF. Cell 103, 321-330 (2000).
9. Shapiro, G. I. Preclinical and clinical development of the cyclin-dependent kinase inhibitorflavopiridol. Clin Cancer Res. 10, S4270-S4275 (2004).
10. Brown, J. M. & Attardi, L. D. The role of apoptosis in cancer development and treatment response. Nature Rev. Cancer 5, 231-237 (2005).
11. Schimmer, A. D. et al. Small-molecule antagonists of apoptosis suppressor XIAP exhibit broad antitumour activity. Cancer Cell 5, 25-35 (2004).
12. Quo, F. et al. Ectopic overexpression of second mitochondria-derived activator of caspases (Smac/ DIABLO) or cotreatment with N-terminus of Smac/ DIABLO peptide potentiates epothilone B derivative-(BMS 247550) and Apo-2L/TRAIL-induced apoptosis. Blood 99, 3419-3426 (2002).
13. Selivanova, G. et al. Reactivation of mutant p53: a new strategy for cancer therapy. Semin. Cancer Biol 8, 369-378 (1998).
14. Vassilev, L. T. et al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303, 844-848 (2004).
15. Honda, T. et al. A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol. Ther. 1, 163-167 (2002).
16. Franke, T. F. et al. PI3K/Akt and apoptosis: size matters, Oncogene 22, 8983-8998 (2003).
17. Luo, J., Manning, B. D. & Cantley, L. C. Targeting the PI3K-Akt pathway in human cancer: rationale and promise. Cancer Cell 4, 257-262 (2003).
18. Fingar, D. C. & Blenis, J. Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression, Oncogene 23, 3151-3171 (2004).
19. Hidalgo, M. & Rowinsky, E. K. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene 19, 6680-6686 (2000).
20. Mita, M. M., Mita, A. & Rowinsky, E. K. Mammalian target of rapamycin: a new molecular target for breast cancer. Clin. Breast Cancer 4, 126-137 (2003).
21. Neshat, M. S. et al. Enhanced sensitivity of PTEN-deficient tumours to inhibition of FRAP/mTOR. Proc. Natl Acad. Sci. USA 98, 10314-10319 (2001).
22. Vermeulen, K., Berneman, Z. N., and Van Bockstaele, D. R. Cell cycle and apoptosis. Cell Prolif. 36, 165-175 (2003).
23. Hurwitz, H, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colourectal cancer. N. Engl. J. Med. 350, 2335-2342 (2004).
24. Powis, G. & Kirkpatrick, L, Hypoxia inducible factor-1α as a cancer drug target. Mol. Cancer Ther. 3, 647-654 (2004).
25. Kung, A. L. et al. Small molecule blockade of transcriptional co-activation of the hypoxia-inducible factor pathway. Cancer Cell 6, 33-43 (2004).
26. Kantarjian, H. et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukaemia. N. Engl. J. Med. 346, 645-652 (2002).
27. Shet, A. S., Jahagirdar, B. N. & Verfaillie, C. M. Chronic myelogenous leukaemia: mechanisms underlying disease progression. Leukaemia 16, 1402-1411 (2002).
28. Gorre, M. E. et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293, 876-880 (2001).
29. Roche-Lestienne, C. & Preudhomme, C, Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment. Semin. Hematol. 40, 80-82 (2003).
30. Roche-Lestienne, C. et al. Several types of mutations of the Abl gene can be found in chronic myeloid leukaemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100, 1014-1018 (2002).
31. Gardembas, M. et al. Results of a prospective phase 2 study combining Imatinib mesylate and cytarabine for the treatment of Philadelphia-positive patients with chronic myelogenous leukaemia in chronic phase. Stood 102, 4298-4305 (2003).
32. Higashi, T. et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukaemia: report of two cases. Am. J. Hematol. 76, 275-278 (2004).
33. Cortes, J., O'Brien, S. & Kantarjian, H. Discontinuation of imatinib therapy after achieving a molecular response. Blood 104, 2204-2205 (2004).
34. Jamieson, C. H, et al. Granulocyte-macrophage progenitors as candidate leukemic stem cells in blast-crisis CML N. Engl. J. Med. 351, 657-667 (2004).
35. Warner, J. K. et al. Concepts of human leukemic development. Oncogene 23, 7164-7177 (2004).
36. Miyamoto, T., Weissman, I. L. & Akashi, K. AML1/ETO-expressing nonleukemic stem cells in acute myelogenous leukaemia with 8;21 chromosomal translocation. Proc. Natl Acad. Sci. USA 97, 7521-7526 (2000).
37. Hope, K. J., Jin, L. & Dick, J. E. Acute myeloid leukaemia originates from a hierarchy of leukemic stem cell classes that differ in self-renewal capacity. Nature immunol. 5, 738-743 (2004).
38. Al-Hajj, M. et al. Prospective identification of tumorigenic breast cancer cells. Proc. Natl Acad. Sci. USA 100, 3983-3988 (2003).
39. Singh, S. K. et al. Identification of human brain tumour initiating cells. Nature 432, 396-401 (2004).
40. Fisher, B. et al. Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J. Natl Cancer Inst. 93, 684-690 (2001).
41. Georgantas, R. W. 3rd et al. Microarray and serial analysis of gene expression analyses identify known and novel transcripts overexpressed in hematopoietic stem cells. Cancer Res. 64, 4434-4441 (2004).
42. Guzman, M. L. et al. Preferential induction of apoptosis for primary human leukemic stem cells. Proc. Natl Acad. Sci. USA 99, 16220-16225 (2002).
43. Fisher, B. et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J. Natl Cancer Inst. 90, 1371-1388 (1998).
44. Lynch, T, J. et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350, 2129-2139 (2004).
45. Paez, J. G. et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304, 1497-1500 (2004).
46. Sordella, R. et al. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305, 1163-1167 (2004).
47. Debiec-Rychter, M. et al. Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group. Eur. J. Cancer 40, 689-695 (2004).
48. Heinrich, M. C. et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumour. J. Clin. Oncol. 21, 4342-4349 (2003).
49. Tsai, C. M. et al. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small cell lung cancer cells. Cancer Res. 56, 1068-1074 (1996).
50. Gumireddy, K. et al. A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance. Proc. Natl Acad. Sci. USA 102, 1992-1997 (2005).
51. Barnett, S. F. et al. Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408 (2005).
52. Lindsley, C. W. et al. Allosteric Akt (PKB) inhibitors: discovery and SAR of isozyme selective inhibitors. Bioorg. Med. Chem. Lett. 15, 761-764 (2005).
53. Buchdunger, E. et al. Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenytaminopyrimidine class. Proc. Natl Acad. Sci. USA 92, 2558-2562 (1995).
54. Buchdunger, E. et al. Inhibition of the Abl protein-tyrosine kinase In vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res, 56, 100-104 (1996).
55. Druker, B. J. et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nature Med. 2, 561-566 (1996).
56. Buchdunger, E. et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J. Pharmacol. Exp. Ther. 295, 139-145 (2000).
57. Shah, N. P. et al. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305, 399-401 (2004).
58. Abrams, T. J. et al. SU11248 inhibits KIT and platelet-derived growth factor receptor β in preclinical models of human small cell lung cancer. Mol. Cancer Ther. 2, 471-478 (2003).
59. Mendel, D. B. et al. In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship, Clin. Cancer Res. 9, 327-337 (2003).
60. O'Farrell, A, M. et al. SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Stood 101, 3597-3605 (2003).
61. Levitzki, A. & Bohmer, F. D. Altered efficacy and selectivity of tyrosine kinase inhibitors of the activated states of protein tyrosine kinases. Anticancer Drug Des. 13. 731-734 (1998).
62. Gangnus. R. et al. Genomic profiling of viable and proliferate micrometastatic cells from early-stage breast cancer patients. Clin. Cancer Res. 10, 3457-3464 (2004).
63. Etzioni, R. et al. The case for early detection. Nature Rev. Cancer 3, 243-252 (2003).
64. von Eschenbach, A. C. A vision for the National Cancer Program in the United States. Nature Rev. Cancer 4, 820-828 (2004).
65. Veenstra, T. D., Prieto. D. A, & Conrads, T. P. Proteomic patterns for early cancer detection. Drug Discov. Today 9, 889-897 (2004).
66. Janne, P. A. & Mayer, R. J. Chemoprevention of colourectal cancer. N. Engl. J. Med. 342, 1960-1968 (2000).
67. Khuri, F. R. & Cohen, V. Molecularly targeted approaches to the Chemoprevention of lung cancer, Clin. Cancer Res 10, S4249-S4253 (2004).